NLS Pharmaceutics' Shares Fall As Data From Narcolepsy Candidate Fails To Cheer Investors

• NLS Pharmaceutics Ltd (NASDAQ: NLSP) announced topline results from its Phase 2a trial evaluating its lead product candidate, Quilience (Mazindol ER), in narcolepsy.

• The trial met its primary endpoint with high statistical significance.

• Treatment with Quilience 3mg per day (NLS-2) resulted in a 7.1 point mean reduction from baseline in excessive daytime sleepiness (EDS) over the 4-week treatment period, compared to a 3.2 point reduction for placebo.

• The two treatment groups separated early and consistently throughout the study, confirming Mazindol ER's rapid onset of action and durable benefit.

• Quilience was well-tolerated, and no safety concerns were identified. No serious adverse events (SAEs) were reported. Regarding the reduction in cataplexy attacks in narcolepsy Type 1 patients (NT1), a key secondary endpoint, Quilience consistently outperformed placebo at all times.

• NLS plans to release interim results from the OLE study before year-end and announce final results in the first quarter of 2023.

• Price Action: NLSP shares are down 12.90% at $0.81 on the last check Tuesday.

See more from Benzinga

• Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment

• Enalare Secures BARDA Award Of $50M For ENA-001 In Drug Overdose

• Desantis Calls Trump 'A Moron Who Has No Business Running For President,' Former Staffers Say: Report

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.